Esperion Therapeutics Stock Price Target and Analyst Ratings (NASDAQ:ESPR)

Analyst Price Target for ESPR

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$52.89

▲ +93.10% Upside Potential

This price target is based on 9 analysts offering 12 month price targets for Esperion Therapeutics in the last 3 months. The average price target is $52.89, with a high forecast of $134.00 and a low forecast of $24.00. The average price target represents a 93.10% upside from the last price of $27.39.

Hold

The current consensus among 9 polled investment analysts is to hold stock in Esperion Therapeutics. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

1 strong buy ratings
5 buy ratings
3 hold ratings
2 sell ratings

Ratings as of

9/6/2019

1 strong buy ratings
4 buy ratings
3 hold ratings
2 sell ratings

Ratings as of

12/5/2019

1 strong buy ratings
6 buy ratings
3 hold ratings
2 sell ratings

Ratings as of

3/4/2020

1 strong buy ratings
5 buy ratings
4 hold ratings
2 sell ratings

Ratings as of

6/2/2020

1 strong buy ratings
6 buy ratings
4 hold ratings
2 sell ratings

Ratings as of

8/31/2020

1 strong buy ratings
6 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

11/29/2020

1 strong buy ratings
6 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

1/28/2021

1 strong buy ratings
4 buy ratings
3 hold ratings
2 sell ratings

Ratings as of

2/27/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
2/25/2021	Needham & Company LLC	Lower Price Target	Strong-Buy	$150.00 ➝ $134.00	High	i
2/12/2021	Jefferies Financial Group	Downgrade	Buy ➝ Hold	$40.00 ➝ $30.00	Low	i
2/9/2021	The Goldman Sachs Group	Downgrade	Neutral ➝ Sell	$44.00 ➝ $24.00	Low	i
1/15/2021	Bank of America	Downgrade	Buy ➝ Neutral	$52.00 ➝ $35.00	High	i
11/10/2020	Credit Suisse Group	Upgrade	Neutral ➝ Outperform	$45.00	Medium	i Rating by Martin Auster at Credit Suisse Group AG
10/15/2020	Bank of America	Lower Price Target	Buy	$55.00 ➝ $52.00	Low	i
9/29/2020	JPMorgan Chase & Co.	Initiated Coverage	Sell	$35.00	Low	i
8/17/2020	Bank of America	Lower Price Target	Buy	$60.00 ➝ $55.00	Low	i
8/11/2020	Needham & Company LLC	Reiterated Rating	Buy	$158.00	High	i Rating by Chad Messer at Needham & Company LLC
8/10/2020	Stifel Nicolaus	Reiterated Rating	Buy	$75.00	High	i Rating by Derek Archila at Stifel Nicolaus
8/10/2020	Credit Suisse Group	Downgrade	Outperform ➝ Neutral	$83.00 ➝ $45.00	High	i Rating by Martin Auster at Credit Suisse Group AG
6/29/2020	Credit Suisse Group	Initiated Coverage	Buy	$83.00	High	i Rating by Martin Auster at Credit Suisse Group AG
6/26/2020	Stifel Nicolaus	Reiterated Rating	Buy	$75.00	High	i Rating by Derek Archila at Stifel Nicolaus
6/23/2020	Northland Securities	Initiated Coverage	Hold	$42.00	High	i Rating by Carl Byrnes at Northland Securities
6/9/2020	Credit Suisse Group	Reiterated Rating	Buy	$87.00	Medium	i Rating by Martin Auster at Credit Suisse Group AG
5/7/2020	Jefferies Financial Group	Lower Price Target	Buy	$85.00 ➝ $70.00	High	i
5/7/2020	Needham & Company LLC	Reiterated Rating	Buy		High	i Rating by Chad Messer at Needham & Company LLC
5/7/2020	Northland Securities	Reiterated Rating	Hold	$42.00	High	i Rating by Carl Byrnes at Northland Securities
5/7/2020	Citigroup	Boost Price Target	Buy	$46.00 ➝ $56.00	High	i
5/6/2020	Stifel Nicolaus	Reiterated Rating	Buy	$76.00	High	i Rating by Derek Archila at Stifel Nicolaus
4/20/2020	Stifel Nicolaus	Reiterated Rating	Buy		Low	i Rating by Derek Archila at Stifel Nicolaus
4/20/2020	Needham & Company LLC	Reiterated Rating	Buy	$158.00	Low	i Rating by Chad Messer at Needham & Company LLC
4/16/2020	Northland Securities	Lower Price Target	Market Perform	$60.00 ➝ $42.00	High	i Rating by Carl Byrnes at Northland Securities
4/6/2020	Needham & Company LLC	Reiterated Rating	Buy	$158.00	High	i Rating by Chad Messer at Needham & Company LLC
4/1/2020	Bank of America	Initiated Coverage	Buy	$50.00	High	i
3/31/2020	Needham & Company LLC	Reiterated Rating	Buy	$158.00	High	i Rating by Chad Messer at Needham & Company LLC
3/17/2020	Citigroup	Upgrade	Neutral ➝ Buy		High	i
2/28/2020	JPMorgan Chase & Co.	Boost Price Target	Neutral	$46.00 ➝ $47.00	Low	i
2/27/2020	Cowen	Reiterated Rating	Buy	$87.00	Medium	i
2/24/2020	Needham & Company LLC	Boost Price Target	Strong-Buy	$144.00 ➝ $158.00	Medium	i
2/24/2020	JMP Securities	Reiterated Rating	Outperform	$191.00	Medium	i
2/23/2020	Stifel Nicolaus	Reiterated Rating	Buy	$83.00	Medium	i Rating by Derek Archila at Stifel Nicolaus
2/23/2020	Northland Securities	Downgrade	Outperform ➝ Market Perform	$60.00	Medium	i Rating by Carl Byrnes at Northland Securities
2/19/2020	BTIG Research	Reiterated Rating	Buy	$90.00	Medium	i
2/14/2020	Citigroup	Downgrade	Buy ➝ Neutral	$73.00 ➝ $82.00	High	i
1/31/2020	Chardan Capital	Reiterated Rating	Hold	$65.00	High	i Rating by Gbola Amusa at Chardan Capital
11/6/2019	Cowen	Reiterated Rating	Buy		Low	i Rating by Chris Shibutani at Cowen Inc
9/17/2019	Stifel Nicolaus	Lower Price Target	Buy	$112.00 ➝ $70.00	Low	i Rating by Derek Archila at Stifel Nicolaus
9/16/2019	The Goldman Sachs Group	Upgrade	Sell ➝ Neutral	$55.00 ➝ $45.00	Medium	i
8/29/2019	Northland Securities	Reiterated Rating	Buy		High	i Rating by Carl Byrnes at Northland Securities
8/8/2019	Northland Securities	Reiterated Rating	Buy		Medium	i Rating by Carl Byrnes at Northland Securities
7/18/2019	Cowen	Reiterated Rating	Buy	$80.00	Low	i Rating by Chris Shibutani at Cowen Inc
6/14/2019	Northland Securities	Set Price Target	Buy	$65.00	Medium	i Rating by Carl Byrnes at Northland Securities
6/13/2019	Stifel Nicolaus	Reiterated Rating	Buy		Low	i Rating by Derek Archila at Stifel Nicolaus
6/13/2019	Cowen	Reiterated Rating	Buy	$85.00	Medium	i Rating by Chris Shibutani at Cowen Inc
5/29/2019	The Goldman Sachs Group	Downgrade	Neutral ➝ Sell	$50.00	Medium	i Rating by Paul Choi at The Goldman Sachs Group, Inc.
5/28/2019	Citigroup	Set Price Target	Buy	$73.00	High	i Rating by Joel Beatty at Citigroup Inc.
5/6/2019	Credit Suisse Group	Boost Price Target	Outperform	$79.00 ➝ $90.00	Medium	i
5/6/2019	Bank of America	Upgrade	Underperform ➝ Neutral		Low	i
5/5/2019	Cowen	Set Price Target	Buy	$94.00	High	i Rating by Chris Shibutani at Cowen Inc
4/26/2019	The Goldman Sachs Group	Upgrade	Sell ➝ Neutral	$50.00	Low	i Rating by Paul Choi at The Goldman Sachs Group, Inc.
4/2/2019	Northland Securities	Set Price Target	Buy	$65.00	Low	i Rating by Carl Byrnes at Northland Securities
3/29/2019	Stifel Nicolaus	Reiterated Rating	Buy	$112.00	Low	i Rating by Derek Archila at Stifel Nicolaus
3/14/2019	Chardan Capital	Reiterated Rating	Hold	$50.00	Medium	i
3/13/2019	JPMorgan Chase & Co.	Upgrade	Underweight ➝ Neutral	$38.00 ➝ $47.00	High	i
3/1/2019	Northland Securities	Reiterated Rating	Buy	$65.00	Low	i Rating by Carl Byrnes at Northland Securities
1/15/2019	Cowen	Reiterated Rating	Buy	$94.00	Low	i Rating by Chris Shibutani at Cowen Inc
1/7/2019	Needham & Company LLC	Boost Price Target	Strong-Buy	$94.00 ➝ $114.00	Low	i
12/13/2018	The Goldman Sachs Group	Initiated Coverage	Sell ➝ Sell	$45.00	High	i Rating by Paul Choi at The Goldman Sachs Group, Inc.
12/10/2018	Stifel Nicolaus	Boost Price Target	Buy ➝ Buy	$89.00 ➝ $104.00	Medium	i
10/29/2018	Northland Securities	Upgrade	Market Perform ➝ Outperform	$65.00	High	i
10/26/2018	Cowen	Set Price Target	Buy	$82.00	Low	i Rating by Chris Shibutani at Cowen Inc
10/16/2018	BTIG Research	Initiated Coverage	Buy ➝ Buy	$82.00	High	i
9/14/2018	Stifel Nicolaus	Initiated Coverage	Buy	$89.00	High	i
8/17/2018	Citigroup	Upgrade	Neutral ➝ Buy	$57.00 ➝ $75.00	Low	i
8/6/2018	Cowen	Reiterated Rating	Buy	$95.00	Low	i
7/20/2018	Chardan Capital	Upgrade	Hold	$32.50	Low	i
7/11/2018	Northland Securities	Downgrade	Outperform ➝ Market Perform		Medium	i
5/16/2018	UBS Group	Set Price Target	Buy	$90.00 ➝ $75.00	Low	i Rating by Carter Gould at UBS Group AG
5/4/2018	Credit Suisse Group	Lower Price Target	Outperform ➝ Outperform	$108.00 ➝ $73.00	N/A	i
5/3/2018	JPMorgan Chase & Co.	Downgrade	Neutral ➝ Underweight	$100.54 ➝ $41.00	High	i
5/3/2018	Deutsche Bank Aktiengesellschaft	Lower Price Target	Buy ➝ Buy	$100.00 ➝ $75.00	High	i Rating by Andrew Peters at Deutsche Bank Aktiengesellschaft
5/2/2018	Bank of America	Reiterated Rating	Buy ➝ Underperform		High	i
4/19/2018	Northland Securities	Boost Price Target	Buy	$100.00 ➝ $121.00	Low	i
3/27/2018	Chardan Capital	Boost Price Target	Neutral ➝ Neutral	$75.00 ➝ $100.00	Low	i
3/9/2018	Deutsche Bank Aktiengesellschaft	Boost Price Target	Buy	$100.00	Low	i
3/8/2018	JMP Securities	Boost Price Target	Outperform	$60.00 ➝ $153.00	High	i
3/7/2018	Stifel Nicolaus	Set Price Target	Buy	$105.00	High	i Rating by Alex Schwartz at Stifel Nicolaus
2/21/2018	UBS Group	Set Price Target	Neutral ➝ Neutral	$88.00 ➝ $90.00	High	i Rating by Carter Gould at UBS Group AG
2/21/2018	JPMorgan Chase & Co.	Reiterated Rating	Neutral ➝ Neutral	$55.00 ➝ $65.00	High	i
2/21/2018	Needham & Company LLC	Reiterated Rating	Strong-Buy ➝ Strong-Buy	$81.00 ➝ $94.00	Low	i
1/22/2018	Citigroup	Downgrade	Buy ➝ Neutral	$77.00 ➝ $96.00	Low	i
1/17/2018	Credit Suisse Group	Initiated Coverage	Outperform ➝ Outperform	$103.00	Low	i
1/17/2018	UBS Group	Set Price Target	Buy ➝ Buy	$62.00 ➝ $88.00	High	i Rating by Carter Gould at UBS Group AG
1/15/2018	Stifel Nicolaus	Set Price Target	Positive ➝ Buy	$70.00 ➝ $105.00	Medium	i Rating by Alex Schwartz at Stifel Nicolaus
1/5/2018	Bank of America	Upgrade	Neutral ➝ Buy	$76.00	High	i
12/14/2017	Needham & Company LLC	Upgrade	Buy ➝ Strong-Buy	$72.00 ➝ $81.00	Medium	i
12/6/2017	Chardan Capital	Boost Price Target	Neutral	$20.00 ➝ $75.00	High	i
12/5/2017	Chardan Capital	Reiterated Rating	Neutral ➝ Neutral	$20.00 ➝ $75.00	High	i
11/10/2017	Northland Securities	Reiterated Rating	Buy	$72.00	N/A	i
10/4/2017	Stifel Nicolaus	Reiterated Rating	Buy	$70.00	Medium	i
10/4/2017	Northland Securities	Reiterated Rating	Buy	$72.00	Medium	i
9/7/2017	Cowen	Initiated Coverage	Outperform	$64.00	Low	i
8/29/2017	Northland Securities	Initiated Coverage	Outperform ➝ Outperform	$72.00	Medium	i
8/21/2017	Jefferies Financial Group	Reiterated Rating	Buy	$85.00	Low	i
8/11/2017	Bank of America	Reiterated Rating	Neutral ➝ Neutral	$60.00	Medium	i
8/10/2017	Stifel Nicolaus	Reiterated Rating	Buy	$60.00 ➝ $70.00	High	i
8/9/2017	Deutsche Bank Aktiengesellschaft	Set Price Target	Buy	$48.00 ➝ $64.00	High	i Rating by Andrew Peters at Deutsche Bank Aktiengesellschaft
8/8/2017	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$85.00 ➝ $55.00	Low	i
8/8/2017	Needham & Company LLC	Boost Price Target	Buy ➝ Positive	$58.00 ➝ $72.00	High	i Rating by Chad Messer at Needham & Company LLC
7/10/2017	Jefferies Financial Group	Initiated Coverage	Hold ➝ Hold	$55.00	Low	i
6/27/2017	UBS Group	Reiterated Rating	Buy	$52.00 ➝ $57.00	N/A	i
6/26/2017	Stifel Nicolaus	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $60.00	Low	i
6/23/2017	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy	$48.00	High	i
6/22/2017	Citigroup	Reiterated Rating	Buy		High	i Rating by Joel Beatty at Citigroup Inc.
3/29/2017	UBS Group	Upgrade	Neutral ➝ Buy	$23.00 ➝ $52.00	N/A	i
3/21/2017	Citigroup	Boost Price Target		$77.00	High	i Rating by Joel Beatty at Citigroup Inc.
3/21/2017	JPMorgan Chase & Co.	Boost Price Target		$22.00 ➝ $50.00	High	i
3/20/2017	JPMorgan Chase & Co.	Reiterated Rating	Hold	$22.00 ➝ $50.00	Medium	i Rating by Jessica Fye at JPMorgan Chase & Co.
3/20/2017	Citigroup	Set Price Target	Buy	$39.00	Medium	i Rating by Joel Beatty at Citigroup Inc.
3/20/2017	Royal Bank of Canada	Reiterated Rating	Hold	$45.00	High	i
3/20/2017	Needham & Company LLC	Boost Price Target	Strong-Buy ➝ Strong-Buy	$25.00 ➝ $58.00	High	i Rating by Chad Messer at Needham & Company LLC
3/20/2017	Credit Suisse Group	Upgrade	Underperform ➝ Neutral	$29.00	High	i
3/18/2017	Needham & Company LLC	Set Price Target	Buy	$25.00	High	i Rating by Chad Messer at Needham & Company LLC
3/13/2017	Citigroup	Set Price Target	Buy	$39.00	Low	i Rating by Joel Beatty at Citigroup Inc.
2/28/2017	Citigroup	Upgrade	Neutral ➝ Buy	$14.00 ➝ $39.00	N/A	i Rating by Joel Beatty at Citigroup Inc.
2/23/2017	Royal Bank of Canada	Reiterated Rating	Sector Perform ➝ Sector Perform	$20.00 ➝ $30.00	N/A	i
2/16/2017	UBS Group	Boost Price Target	Neutral	$11.00 ➝ $23.00	N/A	i
2/7/2017	Royal Bank of Canada	Set Price Target	Hold	$20.00	N/A	i Rating by Michael Yee at Royal Bank of Canada
2/4/2017	Needham & Company LLC	Set Price Target	Buy	$25.00	N/A	i Rating by Chad Messer at Needham & Company LLC
1/10/2017	Needham & Company LLC	Reiterated Rating	Buy	$25.00	N/A	i
1/3/2017	Royal Bank of Canada	Reiterated Rating	Hold	$15.00	N/A	i
12/20/2016	Credit Suisse Group	Reiterated Rating	Sell	$12.00	N/A	i Rating by Vamil Divan at Credit Suisse Group AG
11/14/2016	Citigroup	Downgrade	Buy ➝ Neutral		N/A	i Rating by Joel Beatty at Citigroup Inc.
11/6/2016	JMP Securities	Reiterated Rating	Buy		N/A	i Rating by Jason Butler at JMP Securities
10/15/2016	Stifel Nicolaus	Reiterated Rating	Buy	$64.00 ➝ $30.00	N/A	i Rating by Thomas Shrader at Stifel Nicolaus
10/15/2016	Chardan Capital	Reiterated Rating	Neutral	$12.50	N/A	i Rating by Gbola Amusa MD CFA at Chardan Capital
10/14/2016	Credit Suisse Group	Boost Price Target	Underperform	$10.00 ➝ $14.00	N/A	i Rating by Vamil Divan at Credit Suisse Group AG
10/13/2016	Chardan Capital	Set Price Target	Hold	$13.00	N/A	i Rating by Gbola Amusa MD CFA at Chardan Capital
9/22/2016	Stifel Nicolaus	Reiterated Rating	Buy	$64.00	N/A	i Rating by Thomas Shrader at Stifel Nicolaus
8/31/2016	Barclays	Set Price Target	Hold	$13.00	N/A	i Rating by jonathan eckard at Barclays PLC
8/5/2016	JPMorgan Chase & Co.	Set Price Target	Hold	$15.00	N/A	i Rating by Jessica Fye at JPMorgan Chase & Co.
7/6/2016	Credit Suisse Group	Reiterated Rating	Sell	$10.00	N/A	i Rating by Vamil Divan at Credit Suisse Group AG
7/5/2016	WallachBeth Capital	Downgrade	Buy ➝ Hold	$35.00	N/A	i
7/5/2016	UBS Group	Downgrade	Buy ➝ Neutral	$69.00 ➝ $11.00	N/A	i
6/30/2016	Stifel Nicolaus	Downgrade	Neutral ➝ Underperform	$23.00 ➝ $10.00	N/A	i
6/29/2016	Chardan Capital	Reiterated Rating	Hold	$13.00	N/A	i Rating by Gbola Amusa MD CFA at Chardan Capital
6/29/2016	Needham & Company LLC	Reiterated Rating	Buy	$77.00 ➝ $25.00	N/A	i
6/29/2016	Barclays	Downgrade	Overweight ➝ Equal Weight	$28.00 ➝ $13.00	N/A	i
6/29/2016	Citigroup	Reiterated Rating	Buy	$36.00 ➝ $22.00	N/A	i
6/29/2016	Lake Street Capital	Lower Price Target	Buy	$80.00 ➝ $27.00	N/A	i
6/29/2016	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform	$30.00 ➝ $15.00	N/A	i
6/29/2016	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$50.00 ➝ $15.00	N/A	i
6/29/2016	Credit Suisse Group	Downgrade	Neutral ➝ Underperform	$23.00 ➝ $10.00	N/A	i
6/16/2016	JMP Securities	Reiterated Rating	Buy	$67.00	N/A	i
3/9/2016	JMP Securities	Lower Price Target	Market Outperform	$113.00 ➝ $67.00	N/A	i Rating by Jason Butler at JMP Securities
2/28/2016	Chardan Capital	Reiterated Rating	Hold		N/A	i Rating by Gbola Amusa MD CFA at Chardan Capital

(Data available from 2/27/2016 forward)

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.

Today's Range

Now: $27.39

$26.23

$28.24

50 Day Range

MA: $29.93

$25.12

$36.89

52 Week Range

Now: $27.39

$23.90

$56.85

Volume

699,140 shs

Average Volume

979,607 shs

Market Capitalization

$763.55 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.48

Frequently Asked Questions

What sell-side analysts currently cover shares of Esperion Therapeutics?

The following Wall Street research analysts have issued stock ratings on Esperion Therapeutics in the last year: Bank of America Co., Citigroup Inc., Cowen Inc, Credit Suisse Group AG, Jefferies Financial Group Inc., JPMorgan Chase & Co., Needham & Company LLC, Northland Securities, Stifel Nicolaus, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for ESPR.

What is the current price target for Esperion Therapeutics?

9 Wall Street analysts have set twelve-month price targets for Esperion Therapeutics in the last year. Their average twelve-month price target is $52.89, suggesting a possible upside of 93.1%. Needham & Company LLC has the highest price target set, predicting ESPR will reach $134.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $24.00 for Esperion Therapeutics in the next year.
View the latest price targets for ESPR.

What is the current consensus analyst rating for Esperion Therapeutics?

Esperion Therapeutics currently has 2 sell ratings, 3 hold ratings, 3 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ESPR, but not buy more shares or sell existing shares.
View the latest ratings for ESPR.

What other companies compete with Esperion Therapeutics?

Other companies that are similar to Esperion Therapeutics include Alkermes, OPKO Health, ALX Oncology, Corcept Therapeutics, Viela Bio, Intra-Cellular Therapies, Xencor, Taro Pharmaceutical Industries, Prelude Therapeutics, IGM Biosciences, Global Blood Therapeutics, Amarin, CytoDyn, Deciphera Pharmaceuticals and Axsome Therapeutics.

How do I contact Esperion Therapeutics' investor relations team?

Esperion Therapeutics' physical mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company's listed phone number is 734-887-3903 and its investor relations email address is [email protected] The official website for Esperion Therapeutics is www.esperion.com.

NASDAQ:ESPR - Esperion Therapeutics Stock Price Target and Predictions

Analyst Price Target for ESPR

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Esperion Therapeutics?

What is the current price target for Esperion Therapeutics?

What is the current consensus analyst rating for Esperion Therapeutics?

What other companies compete with Esperion Therapeutics?

How do I contact Esperion Therapeutics' investor relations team?